OREANDA-NEWS. Yokogawa Electric Corporation announces that its confocal image single-cell drug discovery support system has been selected for the Japan Science and Technology Agency's (JST) next-generation technology transfer program (NexTEP). NexTEP was created to promote efforts by companies to find practical applications for the technologies (including those covered by patents) and research findings of universities and public research institutions.

Through this undertaking, JST aims to develop a new drug-discovery support system that will integrate a single-cell mass spectrometry method developed by the RIKEN Quantitative Biology Center's Laboratory for Single Cell Mass Spectrometry with high-speed imaging and high-precision positioning technologies that Yokogawa has developed for its confocal scanner units and drug-discovery support devices.

For the development of new drugs, multiple cells are typically ground to analyze intracellular metabolism and thereby verify the efficacy and side effects of a particular candidate drug. A drawback of this technique is that molecular changes in individual cells cannot be analyzed in sufficient detail. In addition, large numbers of animal and human cells are required.

With this new system, JST aims to clarify how molecules of a candidate drug reach a specific cell and the changes that take place there. Single-cell mass spectrometry is a technique for the analysis of target molecules that have been suctioned out from individual cells as they are being observed under a microscope. The system that is to be developed will speed up this process by automating the identification of cells and molecules where unusual changes have taken place, and automatically capturing target molecules. In addition to speeding up analysis, this will reduce costs.

Yokogawa will work with RIKEN to develop a system that will accelerate the development of new drugs by enabling the quick and precise analysis of the effect that candidate drugs have on intracellular metabolism.